Results 241 to 250 of about 53,113 (297)

Risk of severe infections in patients with triple-negative breast cancer treated with atezolizumab plus nab-paclitaxel: a real-world, postmarketing database study in Japan. [PDF]

Int J Clin Oncol
Yuri A, Nakane S, Miyano Y, Yamada K, Sugano H, Nakatsuji E, Aoki M, Murayama A.   +7 more
europepmc   +1 more source

Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial” [PDF]

Sun Young Yim, Sung-Hwan Lee, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju‐Seog Lee   +5 more
openalex   +1 more source

FoxO3a‐Mediated Modulation of PD‐L1 Expression and Inhibition by Dihydroartemisinin in Triple‐Negative Breast Cancer

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Tumour immunotherapy targeting PD‐1/PD‐L1 shows promise, but the regulatory mechanisms of PD‐L1 and its small‐molecule modulators remain unclear. This study investigated FoxO3a‐mediated PD‐L1 regulation and the PD‐L1‐inhibitory role of dihydroartemisinin (DA) in triple‐negative breast cancer (TNBC).
Xingan Xing, Zhiwei Zhou, Mohd Farhan, Xia Zhao, Shuai Li, Bingxi Lei, Jiankang Fang, Wenshu Zhou, Wenhua Zheng   +8 more
wiley   +1 more source

Real-World Comparative Study of Atezolizumab-Based Chemotherapy Regimens in Advanced Non-Small Cell Lung Cancer. [PDF]

Cancers (Basel)
Ohiwa A, Nishimura T, Sakaguchi T, Fujimoto H, Kodama S, Fujiwara A, Nakahara H, Isobe T, Hirai T, Yagi A, Ebihara A, Ibata H, Hataji O, Yoshida M, Yuda H, Yasuma T, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T.   +18 more
europepmc   +1 more source

317P: Impact of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer (ES-SCLC) [PDF]

Min You, Jiahua Liu, Feifei Teng, Lifang Wu, Han Qin, Y. Zhang, C. Zhang, Zexian Liu, Kuansheng Ma, Xiaoke Hao, J. Li, Pengfei Xing   +11 more
openalex   +1 more source

Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma

Journal of Gastroenterology and Hepatology, Volume 41, Issue 1, Page 302-311, January 2026.
ABSTRACT Background and Aim Data on sequential immune checkpoint inhibitor (ICI) retreatment following initial atezolizumab plus bevacizumab (Atez + Bev) are limited. This study aimed to evaluate the efficacy and safety of sequential ICI retreatment in patients with unresectable hepatocellular carcinoma (uHCC). Methods Of 835 patients with uHCC treated
Takanori Ito, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi, Joji Tani, Tetsu Tomonari, Ryu Sasaki, Kyo Sasaki, Satoru Kakizaki, Takeshi Hatanaka, Hideki Iwamoto, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Tomotake Shirono, Yuki Kanayama, Hisamitsu Miyaaki, Sohji Nishina, Tetsuji Takayama, Hideki Kobara, Motoyuki Otsuka, Taro Takami, Takumi Kawaguchi, Hiroki Kawashima, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group   +24 more
wiley   +1 more source

Evaluation of the Clinical Impact of Immune Checkpoint Inhibitors (Atezolizumab and Pembrolizumab) in the Treatment of Triple-Negative Breast Cancer: A Meta-Analysis and Review of Literature. [PDF]

Cureus
Khan N, Jabeen S.
europepmc   +1 more source

Magnetic resonance imaging features of hypophysitis in patients with cancer treated with immune checkpoint inhibitors

Journal of Neuroendocrinology, Volume 38, Issue 1, January 2026.
This study evaluated pituitary MRI results in cancer patients who experienced immune‐related hypophysitis while receiving immune checkpoint inhibitor treatment. MRI abnormalities were present in 63% of patients at follow‐up and 56% of patients at diagnosis, mostly in patients with multiple hormonal deficiencies.
Anna Angelousi, Stavroula Asimakopoulou, Charis Bourgioti, Amalia Anastasopoulou, Spyridon Kazanas, Panagiotis Diamantopoulos, Athina Karabela, Elisavet Tasouli, Lia‐Angela Moulopoulos, Dimitrios C. Ziogas, Helen Gogas   +10 more
wiley   +1 more source

Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab. [PDF]

J Immunother Cancer
Govindu S, Gowda P, Muquith M, Espinoza M, Hsiehchen D.   +4 more
europepmc   +1 more source

Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B

Liver International, Volume 46, Issue 1, January 2026.
ABSTRACT Background & Aims Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child–Pugh class B (CP‐B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP‐B.
Ryu Sasaki, Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi, Joji Tani, Tetsu Tomonari, Kyo Sasaki, Satoru Kakizaki, Takeshi Hatanaka, Satoshi Miuma, Tomotake Shirono, Hideki Iwamoto, Norikazu Tanabe, Takafumi Yamamoto, Yuki Kanayama, Atsushi Naganuma, Sohji Nishina, Tetsuji Takayama, Hideki Kobara, Motoyuki Otsuka, Hiroki Kawashima, Taro Takami, Takumi Kawaguchi, Hisamitsu Miyaaki, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group   +25 more
wiley   +1 more source